Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Polaris Taiwan Subsidiary TDW To Begin Phase III Trials Of Liver Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago

You may also be interested in...



After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III

With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.

After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III

With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.

Taiwan Creates National Vaccine Fund To Stabilize National Supplies

HONG KONG - Taiwan plans to create a national vaccine fund as early as next year to stabilize the country's supply and streamline decisions on new purchases

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel